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ABSTRACT
There is growing evidence that nerve growth factor (NGF) may
function as a mediator of persistent pain states. We have iden-
tified a novel nonpeptidic molecule, ALE-0540, that inhibits the
binding of NGF to tyrosine kinase (Trk) A or both p75 and TrkA
(IC50 5.88 6 1.87 mM, 3.72 6 1.3 mM, respectively), as well as
signal transduction and biological responses mediated by TrkA
receptors. ALE-0540 was tested in models of neuropathic pain
and thermally-induced inflammatory pain, using two routes of
administration, a systemic i.p. and a spinal intrathecal (i.th.)
route. Morphine was also tested for comparison in the antial-
lodynia model using mechanical stimuli. We show that either
i.p. or i.th. administration of ALE-0540 in rats produced antial-
lodynia in the L5/L6 ligation model of neuropathic pain. The
calculated A50 values (and 95% confidence intervals) for ALE-
0540 administered i.p. and i.th. were 38 (17.5–83) mg/kg and
34.6 (17.3–69.4) mg, respectively. ALE-0540 given i.th., at
doses of 30 and 60 mg, also blocked tactile allodynia in the
thermal sensitization model. Although morphine displayed
greater potency [A50 value of 7.1 (5.6–8.8) mg/kg] than ALE-
0540 in anti-allodynic effect when given i.p. to L5/L6-ligated
rats, it was not active when administered i.th. These data
suggest that a blockade of NGF bioactivity using a NGF recep-
tor antagonist is capable of blocking neuropathic and inflam-
matory pain and further support the hypothesis that NGF is
involved in signaling pathways associated with these pain
states. ALE-0540 represents a nonpeptidic small molecule
which can be used to examine mechanisms leading to the
development of agents for the treatment of pain.
Nerve growth factor (NGF) is a trophic molecule essential
for the survival of sympathetic and small diameter primary
sensory neurons (Crowley et al., 1994) and regulates the
specification of the nociceptive phenotype (Ritter et al.,
1991). Although NGF does not appear to be necessary for
neuronal survival in maturity, there is evidence that it may
regulate the levels of Substance P (SP) and calcitonin gene-
related peptide (CGRP) in mature NGF-sensitive neurons
(Diamond et al., 1987). There is also a wealth of evidence to
suggest that NGF can interact with pain-signaling systems
in adult animals (Lewin and Mendell, 1993). This includes
the selective expression of high-affinity NGF receptors [ty-
rosine kinase (Trk) A receptors] on nociceptive primary af-
ferents (Averill et al., 1995) and the hyperalgesic effects of
exogenously administered NGF in animals (Lewin et al.,
1993) and humans (Petty et al., 1994). In a variety of animal
models of inflammation, including those produced by
Freund’s adjuvant (Donnerer et al., 1992), s.c. carrageenin
(Aloe et al., 1992), and in a rat model of cystitis (Andreev et
al., 1995; McMahon et al., 1995), NGF expression is in-
creased.
In the absence of pharmacological antagonists, several
studies have reported the effects of neutralizing anti-NGF
antibodies on hyperalgesic states. These include attenuation
of behavioral sensitivity, the up-regulation of neuropeptides
SP and CGRP, and inflammation-induced expression of the
immediate early gene c-fos in dorsal horn neurons (Woolf et
al., 1994; Lewin et al., 1994, Woolf and Doubell, 1994). Re-
cently, administration of a novel TrkA-IgG fusion molecule
that sequesters endogenous NGF was shown to produce a
sustained thermal and chemical hypoalgesia in the carra-
geenin model of inflammation (McMahon et al., 1995). These
studies suggest that peripherally produced NGF normally
acts to maintain the sensitivity of nociceptive sensory neu-
rons and that an up-regulation of NGF is responsible for
alterations in pain-related behavior. Therefore, blockade of
NGF production or action has been proposed to provide a
novel class of non-anti-inflammatory analgesics with a spe-
cific action on the sensory hypersensitivity produced by in-
flammation.
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Compared to the strong evidence for involvement of NGF
in inflammatory pain, there is relatively little known about
its role in neuropathic pain. Following nerve injury, damaged
axons degenerate and trigger changes in the endoneurium
known collectively as Wallerian degeneration (WD). Promi-
nent among these changes is the production of NGF by fibro-
blasts, Schwann cells, and macrophages, triggered by cyto-
kines released from endogenous or exogenous phagocytes
(Heumann et al., 1987). In a recent study, the hypothesis
that NGF is involved in the genesis of neuropathic pain was
tested by comparing behavioral responses to mechanical and
thermal pain stimuli following chronic constriction injury in
three strains of mice: C57BL/Ola, which have delayed Wal-
lerian degeneration; C57BL/J, “normals”; and C57BL trans-
genics overexpressing the NGF gene driven by a glial factor
activated protein promoter. For both behavioral tests, it was
reported that Ola mice show minimal sensitivity, C57BL/J
mice show a modest increase, whereas glial factor activated
protein-NGF transgenics show a greater increase (Ramer et
al., 1995). Thus, NGF is also implicated in the development of
pain-related behaviors in this rodent model of neuropathic
pain. In a partially damaged nerve, intact nociceptive axons
could be exposed to elevated levels of NGF, much as occurs in
inflammation, but with the difference that the source of the
NGF is from adjacent, degenerating regions of the endo-
neurium.
Although neutralizing anti-NGF antibodies or TrkA-IgG
may represent new agents in the treatment of some chronic
pain states, they have very limited potential as therapeutics.
Some anti-NGF antibodies have been tested to have cross-
reactivity to other neurotrophins (Murphy et al., 1993). The
supply of TrkA-IgG fusion protein, as any recombinant pro-
tein, may require complex manufacturing and purification
processes. The discovery and development of orally active
small molecule-based drugs which antagonize the action of
NGF could also solve issues of delivery. In the present study,
we report the discovery of ALE-0540, a nonpeptidic hetero-
cyclic molecule that inhibits the binding of NGF to p75 and
TrkA, as well as signal transduction and biological responses
mediated by TrkA receptors. A preliminary assessment of
potential clinical utility of ALE-0540 in neuropathic and
thermally induced inflammatory pain states is also pre-
sented.
Materials and Methods
Binding of 125I-NGF to PC12 Cells. Mouse NGF (2.5S) obtained
from Cedarlane Laboratories (Toronto, Ontario, Canada) was used
for all studies. The iodination of NGF was performed as described
previously (Sutter et al., 1979) and the labeled NGF was purified by
size exclusion chromatography on a PD10 column (Pharmacia, Upp-
sala, Sweden) pre-equilibrated with HKR buffer (10 mM HEPES, pH
7.35) containing 125 mM NaCl, 4.8 mM KCl, 1.3 mM CaCl2, 1.2 mM
MgS04, 1.2 mM KH2P04, 1 mg/ml BSA, and 1 mg/ml glucose). PC12
cells were grown in RPMI 1640 with 10% heat-inactivated donor
horse serum and 5% fetal calf serum. Cells were harvested for
binding by washing off the media with calcium-magnesium-free bal-
anced salt solution (Gey’s solution). Cells were pelleted by centrifu-
gation and suspended in HKR buffer. The binding assay was set up
using 96-well microtiter plates, each well containing 125I-NGF (final
concentration of 0.5 nM), 400,000 cells (for a final concentration of
106 cells/ml), and HKR buffer (for total binding) or brain-derived
nerve factor (BDNF; at 40 nM for TrkA binding) or NGF (at 50 nM
for nonspecific binding). The plates were incubated with shaking for
2 h at 4°C and 100-ml aliquots were transferred to 400-ml microcen-
trifuge tubes containing 200 ml of 10% glycerol in HKR. The tubes
were centrifuged for 1 min at 5,000 rpm, the tip containing the cell
pellet was cut off, and the radioactivity bound to the cells was
determined in a gamma counter. Specific binding was calculated as
the difference between the amount of 125I-NGF bound in the absence
(total) and presence (nonspecific binding) of 50 nM unlabeled NGF.
TrkA binding was determined similarly except 10 nM BDNF was
added in all reactions.
Other Receptor Radioligand-Binding Assays. The affinity of
ALE-0540 for various receptors was determined in radioligand-bind-
ing assays by CEREP (Celle L’Evescault, France) using standard
published methods and experimental conditions. All experiments
were performed in triplicate. In each experiment, the respective
reference compound was simultaneously tested at eight concentra-
tions in duplicate to obtain a competition curve to validate the assay.
Following incubation, membranes or cells in suspension were rapidly
filtered under vacuum through Whatman GF/B or Packard GF/C
filters. The filtered membranes were washed several times with an
ice-cold buffer, and bound radioactivity was measured using a liquid
scintillation counter. Results are expressed as a percentage of inhi-
bition of specific binding obtained in the presence of ALE-0540.
Neurite Outgrowth. Dissociated cells enriched for sensory neu-
rons were prepared from embryonic day 8 chick dorsal root ganglia
(DRG) as described (Dostaler et al., 1996). Neurons were seeded at a
density of 800 to 1000 cells/well in Ham’s F-12 containing 5% fetal
calf serum and NGF at 10 pM into wells of Falcon microculture
plates treated with poly-D-lysin. The cells were incubated with the
test compound (at concentration ranging from 0.1 to 50 mM) at 37°C
in a 5% CO2 atmosphere. The cells on the entire lower horizontal
surface of the well were scored for neurite outgrowth at 18 to 20 h
using an inverted microscope fitted with phase-contrast optics. A
neurite was scored if its caliber from the origin to terminal was
constant and its length was equal or greater than 1.5 cell body
diameters. Neurite growth was corrected for background (no NGF).
TrkA Phosphorylation Assay. TrkA phosphorylation was de-
termined by a modification of the methods described by Ross et al.
(1998). Briefly, PC12 cells were used at 106 cells/ml and incubated
with 40 pM NGF with or without ALE-0540 (at indicated concentra-
tions) for 15 min at 37°C. At the conclusion of the reaction, cells were
washed, lysed, and immunoprecipitated with the anti-TrkA anti-
body. Isolated phosphoproteins were resolved using 6% SDS-poly-
acrylamide gel and Western blot analysis performed with antiphos-
photyrosine 4G10 (Upstate Biotechnology Incorp., Lake Placid, NY)
visualized with enhanced chemiluminescence (Amersham, Piscat-
away, NJ).
Nerve Ligation Injury. Nerve ligation injury was performed
according to the method described previously (Kim and Chung,
1992). This technique produces signs of tactile allodynia and thermal
hyperalgesia. Rats were anesthetized with halothane and the L5 and
L6 spinal nerves were exposed, carefully isolated, and tightly ligated
with 4-0 silk suture distal to the DRG. After ensuring homeostatic
stability, the wounds were sutured, and the animals were allowed to
recover in individual cages. Sham-operated rats were prepared in an
identical fashion except that the L5 and L6 spinal nerves were not
ligated.
Intrathecal Catheter Placement. Two routes of administra-
tion, a systemic i.p. and a spinal intrathecal (i.th.) route, were used
explore the activity of compounds. For the spinal route, test com-
pounds were injected through indwelling i.th. catheters in the man-
ner described by Yaksh and Rudy (1976). While under anesthesia,
polyethylene tubing 10 tubing (8 cm) was inserted through an inci-
sion made in the atlanto-occipital membrane to the level of the
lumbar enlargement of the rat and secured. Drug injections were
made in a volume of 5 ml followed by a 9-ml saline flush.
Thermal Sensitization. Rats were lightly anesthetized with
ether. The left hindpaw was placed in a water bath maintained at
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50°C for 1 min. Inflammation suggested by rubor of the paw devel-
oped immediately. The rats were allowed to recover from anesthesia
and tactile testing was begun 2 h after thermal sensitization. This
procedure has produced signs of thermal hyperalgesia and tactile
allodynia that persisted for over 12 h.
Evaluation of Tactile Allodynia. Mechanical allodynia was
determined in the manner described previously (Chaplan et al.,
1994). The paw withdrawal threshold was determined in response to
probing with calibrated von Frey filaments. The rats were kept in
suspended cages with wire mesh floors and the von Frey filaments
were applied perpendicularly to the planar surface of the paw of the
rat until it bent slightly, and was held for 3 to 6 s, or until the paw
is withdrawn. A positive response was indicated by a sharp with-
drawal of the paw. The 50% paw withdrawal threshold was deter-
mined by the nonparametric method (Dixon, 1980). Data were con-
verted to percentage of antiallodynia by the formula:
% Antiallodynia 5 100
3 (test value 2 control value) / (15 g 2 control value)
Results
Pharmacological Characterization of ALE-0540. The
cell line PC12 (Greene and Tischler, 1976) expresses both
types of NGF receptor, with p75 representing approximately
90% and TrkA representing approximately 10% of the NGF-
binding sites. A low-volume screening of commercial com-
pound libraries was completed using the PC12 cells in ligand-
binding experiments, as described in Materials and Methods.
From our screening efforts, we identified a compound, ALE-
0540 (N-{5-nitro-1H-benz[de]isoquinoline-1,3(2H)-dione}-2-
aminoethanol; Fig. 1) that displayed significant ($ 50%) in-
hibition of 125I-NGF binding at 100 mM. A typical
competition binding isotherm of ALE-0540 for 125I-NGF
binding to PC12 cells in the presence or absence of BDNF is
shown in Fig. 2. ALE-0540 displaced 125I-NGF binding in a
concentration-dependent manner, in four independent exper-
iments, with IC50 (mean 6 S.E.M.) of 5.88 6 1.87 mM at the
TrkA and 3.72 6 1.3 mM for both TrkA and p75.
ALE-0540 was assessed for its binding to a battery of
receptors at 1 or 10 mM concentration (Table 1). As can be
seen, ALE-0540 was mostly inactive; less than 20% inhibition
at 1 or 10 mM at A3, cannabinoid 2, endothelin (ET) A, H1,
opioid (d, k, and m) and 5-hydroxytryptamine (5-HT) type 2A
receptors.
Functional Characterization of ALE-0540. Effects of
ALE-0540 on NGF-mediated neurite outgrowth of DRG neu-
rons were quantitated. ALE-0540 showed significant inhibi-
tion of neurite extension in a concentration-dependent man-
ner (Fig. 3). NGF induces a rapid increase in phosphorylation
of tyrosine residues within TrkA receptor as part of signal
transduction cascade. Using conditions where a rapid in-
crease in TrkA phosphorylation is induced by NGF, ALE-
0540 prevented phosphorylation of this receptor dose-depen-
Fig. 1. Structure of ALE-0540.
Fig. 2. Inhibition of 125I-NGF binding to PC12 cells. f, inhibition in the
presence of BDNF; , inhibition in the absence of BDNF.
Fig. 3. Effects of ALE-0540 on neurite outgrowth. The ability of ALE-
0540 to inhibit NGF-induced neurite outgrowth in DRG neurons was
evaluated in the presence of varying concentrations of ALE-0540. Error
bars, S.E.M.
TABLE 1
Competition by ALE-0540 for ligands binding at selected receptors
Receptor IC50, mM (mean 6 S.E.M.)
TrkA 5.88 6 1.87
P75 1 TrkA 3.72 6 1.3
% Inhibition, 1 mM
A3 14
a2c 17
CB2 ,10
ETA ,10
H1 ,10
d ,10
k ,10
m ,10
% Inhibition, 10 mM
A1 14
5HT2A ,10
1999 Antiallodynic Effects of ALE-0540 1273
 at A
SPET Journals on O
ctober 14, 2014
jpet.aspetjournals.org
D
ow
nloaded from
 
dently and exhibited an EC50 value of 28 6 21 mM (n 3) (Figs.
4 and 5).
Antiallodynic Activity of ALE-0540. The L5/L6 nerve-
ligation model is commonly accepted as representing some
aspects of neuropathic pain and critically does not represent
inflammatory pain. In the nerve-injury experiments, ALE-
0540 was tested for mechanical antiallodynic activity com-
pared to actions in sham-operated animals. ALE-0540 pro-
duced dose-dependent antiallodynia after either i.p. or i.th.
injection in rats with L5/L6 nerve ligations (Fig. 6). The
calculated A50 value [and 95% confidence intervals (CIs)] for
ALE-0540 administered i.p. was 38 (17.5–83) mg/kg, indicat-
ing a reduced potency compared to i.p. morphine which dis-
played an A50 (and 95% CIs) of 7.1 (5.6–8.8) mg/kg; however,
both were equally efficacious. In contrast to morphine given
i.th., which was inactive up to 100 mg, ALE-0540 produced
concentration-dependent antiallodynia with an A50 (and 95%
CIs) of 34.6 (17.3–69.4) mg (Fig. 6B). ALE-0540 did not block
tactile allodynia at a concentration of 100 mg when given
directly into a lateral cerebral ventricle (i.c.v.) (data not
shown).
ALE-0540 blocked tactile allodynia produced by thermal
sensitization of the hindpaw of rats at doses of 30 and 60 mg
i.th.(Fig. 7). Antiallodynia ranged from 55 6 21 to 64 6 23
(mean 6 S.E.M.) perecentage of antiallodynia at these doses.
Discussion
This report describes the discovery of a nonpeptidic mole-
cule, ALE-0540, capable of inhibiting NGF binding to PC12
cells in the presence and absence of BDNF. Inhibition of NGF
binding to PC12 cells by ALE-0540 appears to be through
blockade of its receptors as shown by the IC50 values at TrkA
and both p75 and TrkA. Preliminary experiments also dem-
onstrate that ALE-0540 does not bind to NGF, within the
detection limits of an NGF-affinity chromatography column
(G.M.R. and R. Riopelle, unpublished observations). There-
fore, we hypothesize that ALE-0540 is unlike PD 90780
(Speigel et al., 1995) or kynurenic acid derivatives (Jaen et
al., 1995) which have been shown to prevent binding of NGF
to p75 by specifically binding to the NGF molecule.
Consistent with the ability of ALE-0540 to inhibit binding
of NGF to its receptor sites is the demonstration that it
inhibited NGF-induced neurite outgrowth of DRG neurons
(Dostaler et al., 1996). Accompanying the loss in NGF bind-
ing and biological function is the inhibition of TrkA phos-
phorylation induced by NGF, a key initial event in the signal
transduction pathway mediated by this receptor (Kaplan et
al., 1991). This study did not determine the effects of ALE-
0540 on p75-mediated signaling.
Nociceptive responses to experimentally induced pain are
the most important measures in laboratory animal tests of
the analgesic efficacy of novel drugs. As indicated above,
there is selective expression of TrkA receptors on nociceptive
primary afferents (Averill et al., 1995). In the absence of
pharmacological antagonists, NGF neutralizing antibodies or
TrkA-IgG fusion protein have attenuated hyperalgesia in
several models of inflammation (Woolf et al., 1994; Lewin et
al., 1994; McMahon et al., 1995). The goal of testing ALE-
0540 in models of inflammatory pain and neuropathic pain
was to assess its potential clinical utility in these different
pain states. ALE-0540 was effective in inducing antiallodynic
activity after i.p. and i.th. injections following L5/L6 nerve
injury in rats. Although systemic (i.p.) morphine was more
effective than ALE-0540 in inducing antiallodynia, it was not
active by the i.th. route of administration. These results
confirm previous findings that morphine is less effective in
inducing antinociception at the spinal level after peripheral
nerve injury in rats (Xu and Wiesenfeld-Hallin, 1991; Nichols
et al., 1995). The mechanism for a lack (or reduced) effect of
spinal morphine on neuropathic pain is not fully understood,
Fig. 4. Effects of ALE-0540 on TrkA phosphorylation. The ability of
ALE-0540 to prevent NGF-induced phosphorylation of the TrkA receptor
was evaluated by antiphosphotyrosine Western blotting of the TrkA
receptor isolated by immunoprecipitation. ALE-0540 prevented phos-
phorylation observed in the presence of 40 pM NGF. Densitometry of the
gels revealed an EC50 28 6 21 mM (n 3).
Fig. 5. Inhibition of NGF-induced TrkA phosphorylation by ALE-0540.
PC12 cells (at 106 cells/ml) were incubated with 40 pM NGF with or
without ALE-0540 (at indicated concentrations) for 15 min at 37°C.
Afterwards, cells were washed, lysed, and immunoprecipitated with anti-
TrkA antibody. Isolated phosphoproteins were resolved using a 6% SDS-
polyacrylamide gel and Western blot analysis performed with antiphos-
photyrosine 4G10 visualized with enhanced chemiluminescence. Results
are expressed as mean 6 S.E.M. (n 3).
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but some studies are emerging which indicate that it may
share some features with morphine tolerance (Wiesenfeld-
Hallin and Xu, 1996) or it may be due to a reduction in
available m receptors from degeneration of primary efferents
following nerve injury (Nichols et al., 1995). It is significant
that i.th. administration of ALE-0540 attenuated mechanical
allodynia in animals with nerve ligation injury, which sug-
gests a principally spinal site of action. This is also reinforced
by the relative lack of efficacy of ALE-0540 after i.c.v. admin-
istration. If ALE-0540 acts mainly through the spinal route,
it may produce analgesia without side effects associated with
centrally acting analgesics (Porreca et al., 1983; Max et al.,
1988).
The mechanism by which ALE-0540 attenuated mechani-
cal allodynia in the L5/L6-ligated rats is still a matter of
future investigations. It is clear, however, that it must inter-
fere in some manner with injury-induced sensitization of the
dorsal horn neurons which is fundamental to the develop-
ment of hyperalgesia and allodynia associated with neuro-
pathic pain (Woolf et al., 1994). Drawing on recent studies by
Chung et al. (1993) and Ramer and Bisby (1997), both chronic
constriction injury and L5/L6 spinal ligation models produce
rapid sympathetic sprouting into the DRG coincident with
behavioral signs of neuropathic pain. In these animal models,
mechanisms such as inflammation and/or a cytokine role for
NGF cannot be ruled out. We propose that ALE-0540 may act
by blocking NGF-dependent sprouting of TrkA-expressing
sensory and sympathetic axons.
To our knowledge, ALE-0540 serves as the first nonpep-
tidic NGF receptor antagonist molecule to be discovered to
have antiallodynic effects in thermally induced inflammatory
and neuropathic pain models. Its profile indicates lack of
significant interaction with known analgesic targets includ-
ing }2, A1, H1, endothelin A, 5-hydroxytrypyamine type 2,
cannabinoid 2, and opioid (m, d, and k) receptors (Pertovaara
et al. 1990; Karlsten et al., 1991, Mazzari et al., 1996; Suh et
al., 1996; May et al., 1996). As a first generation NGF recep-
tor antagonist, it may be useful as an agent to examine the
roles of p75 and TrkA receptor antagonists as antinociceptive
agents. Coupled with previous findings that NGF can induce
hyperalgesia (Andreev et al., 1995; Ramer et al., 1995), our
present findings further support the hypothesis that NGF is
involved in signaling pathways associated with persistent
pain states.
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